NASD · Healthcare · Biotechnology · USA
Omeros Corp is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Omeros is a biotechnology company that discovers and develops protein and small-molecule therapies targeting immune system regulation, cancer, and substance use disorders. The company markets YARTEMLEA, an approved treatment for a stem cell transplant complication, and maintains development programs for small-molecule inhibitors across ophthalmology, oncology, and other therapeutic areas.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Omeros Corp stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings do not cover four fiscal years in a row, which projecting growth needs.
17 more funds hold it; the full list is part of the paid plan.
137 more in this industry show a wider margin of safety.
We do not publish a verdict on OMER yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive do not cover four fiscal years in a row. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-20 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive do not cover four fiscal years in a row. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.